Hillsdale Investment Management Inc. Raises Holdings in Abbott Laboratories $ABT

Hillsdale Investment Management Inc. lifted its holdings in Abbott Laboratories (NYSE:ABT) by 665.0% in the 1st quarter, Holdings Channel reports. The firm owned 10,480 shares of the healthcare product maker’s stock after acquiring an additional 9,110 shares during the period. Hillsdale Investment Management Inc.’s holdings in Abbott Laboratories were worth $1,076,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. MidAtlantic Capital Management Inc. bought a new position in Abbott Laboratories during the 4th quarter valued at about $25,000. Cornerstone Financial Management LLC purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at approximately $25,000. Purpose Unlimited Inc. bought a new position in Abbott Laboratories during the fourth quarter valued at approximately $25,000. Portfolio Resources Advisor Group Inc. purchased a new stake in Abbott Laboratories in the fourth quarter worth approximately $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories in the fourth quarter worth approximately $26,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Trading Up 10.7%

Shares of Abbott Laboratories stock opened at $98.81 on Friday. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The company’s fifty day simple moving average is $89.56 and its 200-day simple moving average is $102.18. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The stock has a market capitalization of $172.11 billion, a PE ratio of 27.68, a P/E/G ratio of 1.54 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm had revenue of $12.51 billion during the quarter, compared to analyst estimates of $12.52 billion. During the same period in the prior year, the business posted $1.26 EPS. Abbott Laboratories’s revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.48 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.6%. Abbott Laboratories’s dividend payout ratio is presently 70.59%.

Insider Activity

In other news, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Monday, April 27th. The stock was bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. The trade was a 0.15% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Philip P. Boudreau purchased 2,200 shares of the stock in a transaction on Thursday, April 23rd. The shares were purchased at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is owned by company insiders.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott beat Q2 expectations with adjusted EPS of $1.31 versus $1.28 expected, showing better-than-expected profitability. Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
• Positive Sentiment: The company raised 2026 adjusted EPS guidance to $5.45-$5.60, above its prior range, signaling confidence in earnings momentum. Abbott raises 2026 profit forecast on heart device strength
• Positive Sentiment: Revenue grew 13% year over year, supported by strong demand in medical devices, diagnostics, and emerging markets, which points to broad-based operating strength. Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
• Positive Sentiment: Heart-device demand and diagnostics growth, including a surge in sales tied to that segment, improved investor sentiment around Abbott’s longer-term growth profile. Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market
• Neutral Sentiment: Abbott’s profit fell sharply from a year ago on a GAAP basis, but the decline was offset by stronger sales and guidance, making this more of a quality-over-headline-results story. Abbott Laboratories Sales Rise on Diagnostics Growth
• Negative Sentiment: Broader market and tech sell-off headlines may have slightly tempered enthusiasm, but they were not the main driver of ABT’s move. Stock Market Today, July 16: Micron Plunges as Tech Stocks Extend Sell-Off

Analysts Set New Price Targets

A number of equities research analysts have weighed in on ABT shares. Mizuho decreased their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research note on Friday, April 17th. Royal Bank Of Canada cut their price objective on Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating for the company in a report on Friday, April 17th. Citigroup reduced their price objective on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating for the company in a research report on Friday, April 17th. The Goldman Sachs Group dropped their target price on Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a research report on Wednesday, May 27th. Finally, Benchmark cut their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $117.61.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.